Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Joint pain

Uncertainty on long-term efficacy of osteoarthritis medicines

Out of 31 medicines used to treat knee osteoarthritis, only glucosamine sulphate was associated with significant decreases in pain compared with placebo, research has shown.

Osteoarthritis knee X ray

Source: Shutterstock.com

Medicines for knee osteoarthritis may not be effective in the long term, study shows

There is a lack of evidence that medicines for osteoarthritis are effective in the long term, according to a review in the Journal of the American Medical Association (25 December 2018)[1].

The network meta-analysis used data from 47 randomised controlled trials lasting at least 12 months, including 22,037 people with knee osteoarthritis, which explored the effects of 31 medicines on pain, 13 medicines on physical function and 16 medicines on joint structure.

The team found that only celecoxib and prescription glucosamine sulphate were associated with significant decreases in pain compared with placebo. In subanalyses, including those that excluded studies at high risk of bias, these results only remained significant for prescription glucosamine sulphate.

Glucosamine sulphate was also associated with improvement in physical function and joint structure while celecoxib was not.

While there is good evidence for the efficacy of pharmacological agents in short-term pain relief, much research in osteoarthritis has not considered long-term outcomes, the researchers explained.

“Larger randomised clinical trials are needed to resolve the uncertainty around the long-term efficacy of medications for knee osteoarthritis,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206100

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Clinical Pharmaceutics (An)

    Introduction to Clinical Pharmaceutics (An)

    This unique textbook covers the role of basic pharmaceutics in clinical outcomes and in explaining the behaviour of medicines in the body.

    £27.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.